Assessment of clinical outcomes of sorafenib in patients with pulmonary metastatic renal cell carcinoma using computed tomography texture analysis

Yang LI,Guangyu WU,Lei LI,Shiteng SUO,Zeng'ai CHEN

2017-01-01

Abstract:Objective To assess the role of CT texture analysis in predicting tumor response treatment with sorafenib (an antiangiogenic-targeted drug) in patients with pulmonary metastatic renal cell carcinoma.Methods A total of 87 patients who had pulmonary metastatic renal cell carcinoma and were treated with sorafenib were enrolled in this study.All patients underwent the computed tomography plain scan at baseline and the first evaluation (after two cycles of treatment).Clinical outcomes were evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST).The patients were divided into exploration sample group (n =60,enrolled from June 2008 to January 2009) and validation sample group (n =27,enrolled from February 2009 to January 2011).Meanwhile,the patients were subdivided into two groups according to the progression free survival (PFS):PFS≥1 year group and PFS＜ 1 year group.Tumor diameter,attenuation value,entropy,and uniformity of the exploration sample group were examined by receiver operating characteristic (ROC) analysis and stepwise discriminant analysis.The threshold value derived from ROC analysis and discriminant function of the exploration sample group were also used in the validation sample group.Then these parameters were compared with the result of RECIST using Kaplan-Meier survival curves.Results In the exploration sample group,tumor diameter after treatment was significantly larger than that before treatment (P =0.03 and 0.04),but there were no significant differences in the other radiological parameters (filtration or without filtration) between pre-and post-treatment (all P＞0.05).Neither were any metrics in the validation sample group (all P＞0.05).Kaplan-Meier curves showed that discriminant analysis was superior to RECIST alone in assessment of the clinical outcomes in both groups (P =0.02 and 0.04).In the validation sample group,P values of RECIST and percentage change for attenuation were 0.21 and 0.49;P values of entropy were 0.47,0.89,0.72,0.73 and 0.58 when not using filtration and at the filtration coefficients of 1.0,1.5,2.0,and 2.5,respectively,and the P values of uniformity were 0.53,0.72,0.51,0.39,and 0.16.Conclusion Combined with the changes of radiological parameters,including size,attenuation value,entropy and uniformity between pre-and post-treatment,discrimination analysis can help to give a more accurate response assessment to antiangiogenic drugs than RECIST criteria in patients with pulmonary metastatic renal cell carcinoma.